TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01819831

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: proton radiation
Description: proton radiation: 2 GyE/Day to isocenter, one treatment per day, 5 days per week for 25 treatments (=50 GyE to isocenter/25 fractions)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery (wide local excision; limb preservation surgery)
Description: In areas with ample soft tissue that can be removed without compromising future function or wound closure, wide margins is the goal of treatment; associated rates of local failure are low in such instances. Margins will be determined by the surgeon; the goal is to achieve at least a 2 mm negative margin resection. However, smaller margins can be acceptable if it allows for limb-sparing surgery with conserved functional outcomes. Every effort will be made to have limb preservation surgery unless there is documented evidence of tumor progression during or after the course of radiation that would require amputation for an appropriate margin resection.
Study: NCT01560793

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX161 [STF2.HA5 H5N1]
Description: dose escalating, 2 intramuscular doses given 21 days apart
Study: NCT00970567

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Different insulin therapy at different time points
Description: different insulin therapy after positive blood ketones

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Different insulin therapy at different time points
Description: different insulin therapy after positive blood ketones

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Different insulin therapy at different time points
Description: different insulin therapy after positive blood ketones
Study: NCT01749137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: Daily subcutaneous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily subcutaneous infusion
Study: NCT02598544

Intervention type: OTHER
Group type: OTHER
Intervention: adipose tissue sampling
Description: adipose tissue (subcutaneous and visceral adipose tissue) sampling during abdominal surgery and phenotype determination

Intervention type: OTHER
Group type: OTHER
Intervention: adipose tissue sampling
Description: adipose tissue (subcutaneous and visceral adipose tissue) sampling during abdominal surgery and phenotype determination

Intervention type: OTHER
Group type: OTHER
Intervention: adipose tissue sampling
Description: adipose tissue (subcutaneous and visceral adipose tissue) sampling during abdominal surgery and phenotype determination
Study: NCT02826902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol and remifentanil
Description: Anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desflurane and remifentanil
Description: Anesthesia is induced and maintained with desflurane and remifentanil
Study: NCT03791723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan
Description: After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 50 mg LCZ696 for 2-4 weeks, then uptitrated to 100 mg bid for 2-4 weeks, and thereafter, uptitrated to 200 mg bid or tolerable maximum dose ≥6 months.
Study: NCT03558854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
Study: NCT01559597

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid vaccine
Description: Two doses of tetanus toxoid vaccine separated at least 4 weeks. One arm receives the vaccine kept in cold chain and the other arm receives the vaccine kept in CTC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus toxoid vaccine
Description: Two doses of tetanus toxoid vaccine separated at least 4 weeks. One arm receives the vaccine kept in cold chain and the other arm receives the vaccine kept in CTC
Study: NCT03233711

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Rectal Examination
Description: Undergo digital rectal examination
Study: NCT03700775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Telemonitoring
Description: Using the telemedicine kit, participants will record a daily health session including 2 BP measurements obtained one minute apart. Participants are encouraged to record a health session every day, with a minimum of 5 days per week. Participants are also encouraged to equally divide health session recordings between the mornings and evenings. Every 2 weeks BP measurements will be assessed. If less than 75% of measurements are at goal \<130/80 mmHg, the central Telehealth pharmacist will designate drug-therapy intensification according to an evidence-based treatment algorithm that is physician approved. Regardless of BP control, participants will be contacted by their nurse coordinator every 2 weeks. During all telephone visits nurse coordinators emphasize healthy lifestyle habits. Safety protocols are in place for dangerously high or low BP recordings.
Study: NCT01927237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HLR

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HLR
Study: NCT03233711

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Digital Rectal Examination
Description: Undergo digital rectal examination

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Resolution Anoscopy
Description: Undergo anoscopy
Study: NCT01927237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EHR

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EHR
Study: NCT05166824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TempSure
Description: Radiofrequency platform

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TempSure
Description: Radiofrequency platform

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TempSure
Description: Radiofrequency platform
Study: NCT03233711

Intervention type: PROCEDURE
Group type: OTHER
Intervention: High Resolution Anoscopy
Description: Undergo anoscopy
Study: NCT00422240

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gel Vehicle
Description: Participants were treated with gel vehicle topically daily in the evening for 12 Weeks.
Study: NCT01197794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: AZD1981 twice daily
Study: NCT05166824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TempSure
Description: Radiofrequency platform

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scalpel
Description: Cold knife

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bovie
Description: Electrosurgery and electrocautery platform

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pelleve
Description: Radiofrequency platform
Study: NCT00164775

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipramine
Description: 25mg nocte for first 2 weeks then 50 mg nocte for 10 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tab nocte for first 2 weeks then 2 tabs for 10 weeks
Study: NCT04533581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME-401
Description: In the first 2 cycles (1 cycle is 28 days), subjects will be administered 60 mg of ME-401 orally once a day on a continuous schedule (CS). After that, subjects will be administered 60 mg of ME-401 orally once a day for the first 7 days, followed by rest for 21 days on an intermittent schedule (IS).
Study: NCT04077827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Patients will be divided into 2 groups. The TIVA group (N = 23) will be administrated intravenous anesthesia (propofol-remifentanil), while to the DES group (N = 23) volatile anesthetics (desflurane-remifentanil)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Patients will be divided into 2 groups. The TIVA group (N = 23) will be administrated intravenous anesthesia (propofol-remifentanil), while to the DES group (N = 23) volatile anesthetics (desflurane-remifentanil)
Study: NCT00724022

Intervention type: DRUG
Group type: OTHER
Intervention: Basiliximab, Tacrolimus, MMF, Prednisolon
Description: Control group. Therapy with Prednisolon.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab, Tacrolimus, MMF
Description: No Prednisolon after 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus, MMF, rATG
Description: Induction therapy: rATG instead of Basiliximab. No Prednisolon.
Study: NCT01095445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)
Description: Dosage Form: Pegetron - powder for solution; Rebetol - capsules Strength: Pegetron Redipen - 120 mcg per pen; Rebetol - 200 mg Route of Administration: Pegetron - subcutaneous; Rebetol - oral
Study: NCT04397107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Patients were received low dose recombinant human Interleukin-2
Study: NCT03947372

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Appendectomy
Description: removal of acutely inflamed appendix

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Appendectomy
Description: removal of acutely inflamed appendix
Study: NCT03506282

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Running while listening to a traffic audio track
Description: While running three 2-minute sets at different velocities (6, 8 and 10 km/h, respectively) on a sensorized treadmill, each participant will be exposed via earphones to an audio track resembling average outdoor conditions (70 dB).
Study: NCT01197794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: AZD1981 twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: AZD1981 twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: AZD1981 twice daily
Study: NCT03506282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Running with music at moderate volume
Description: While running three 2-minute sets at different velocities (6, 8 and 10 km/h, respectively) on a sensorized treadmill, each participant will be provided the same music track (We take care of our own, by Bruce Springsteen from the Wrecking Ball album, 2012). The music track will be given at a moderate volume (80 dB).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Running with music at moderate-to-high volume
Description: While running three 2-minute sets at different velocities (6, 8 and 10 km/h, respectively) on a sensorized treadmill, each participant will be provided the same music track (We take care of our own, by Bruce Springsteen from the Wrecking Ball album, 2012). The music track will be given at a moderate-to-high volume (85 dB).
Study: NCT01806298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saizen® solution for injection (referred as Saizen®)
Description: Saizen® solution for injection will be administered subcutaneously daily for 39 weeks according to locally approved product labeling for the currently marketed formulation of Saizen®.
Study: NCT06485765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet planning
Description: Healthy eating planning
Study: NCT00669227

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: autologous stem cells
Description: intracoronary administration at the same day of cell aspiration using the stop flow technique

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo suspension
Description: intracoronary administration at the same day as cell aspiration
Study: NCT02418598

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Cohort1
Description: AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 3x10\^11 vg/subject.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Cohort2
Description: AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 9x10\^11 vg/subject.
Study: NCT01197794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: AZD1981 once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: AZD1981 once daily
Study: NCT01694472

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAGE-A4 TCR Gene-Modified T Cells
Description: The study consists of a 2-dose escalation scheme, and the patient receives twice in each dose. The starting dose is 1-3 x 10\^9 cells of each TCR gene-modified cells and the second one is 3-8 x 10\^9 cells of each TCR gene-modified cells. Two weeks after the first infusion the patient receives the same dose again, followed by infusions of IL-2 for 5 days. Thereafter, the patient receives peptide vaccinations on days 21 and 28.
Study: NCT03791723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 40 mg Valsartan daily (qd) for 2-4 weeks, then were uptitrated to 80mg qd or tolerable maximum dose ≥6 months.
Study: NCT00661011

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lobectomy followed by concomitant mediastinal chemoradiotherapy
Description: Lobectomy Radiotherapy 66 Gy in 2 Gy/ fraction, 5 fractions/wk Chemotherapy Cisplatin 60 mg/m² on days 1 and 22 and Vinorelbine 15 mg/m² on days 1, 8, 22 and 29
Study: NCT01912365

Intervention type: PROCEDURE
Intervention: Above Elbow Cast
Study: NCT04197050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril / Valsartan Oral Tablet
Description: After recruiting participants and collecting the baseline information, sacubitril/valsartan group will receive sacubitril/valsartan and optimal pharmaceutical treatment (OPT). The control group will receive valsartan and OPT. A CMR scan and a post-processed imaging procedure will later be carried on in order to detect the cardiac impairment.
Study: NCT04587063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear Appeals
Description: Email

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message about Future Healthcare Costs
Description: Email

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endorsement from a Doctor
Description: Email

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comparison Table
Description: Email

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Highlighting Cost Savings and Convenience
Description: Email
Study: NCT01197794

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match AZD1981
Study: NCT04587063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Highlighting Cost Savings and Convenience
Description: Email

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Highlighting Cost Savings and Convenience
Description: Email

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Highlighting Cost Savings and Convenience
Description: Email
Study: NCT00975403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dead space breathing
Description: Chemical loading by adding a deadspace (600ml) to the breathing circuit during a single cycle exercise test

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Room air breathing
Description: Sham comparator (vs deadspace) during a single cycle exercise test will entail breathing room air on the same circuit without the rebreathe valves
Study: NCT03553953

Intervention type: DEVICE
Intervention: BIS device
Description: Recording data from BIS device from patients who undergo elective surgery under general anesthesia
Study: NCT04237337

Intervention type: OTHER
Intervention: Exposure to MS drugs
Description: Exposure in ICSRs to MS drugs (dichotomous, exposed/not exposed), for each individual MS drug

Intervention type: OTHER
Intervention: Exposure to MS drugs
Description: Exposure in ICSRs to MS drugs (dichotomous, exposed/not exposed), for each individual MS drug
Study: NCT04447339

Intervention type: PROCEDURE
Intervention: Nipple Sparing Mastectomy
Description: Prophylactic open NSM procedures
Study: NCT00760851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: probiotic strain Bb-12
Description: 10\^9 CFU Bb-12 per 4 oz yogurt

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no Bb-12
Description: yogurt identical to intervention yogurt, only without Bb-12 added.
Study: NCT04307576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omitted Doxorubicin
Description: Omission of IV Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omitted Doxorubicin
Description: Omission of IV Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omitted Vincristine+Dexamethasone pulses
Description: Omission of Vincristine+Dexamethasone pulses
Study: NCT01912365

Intervention type: PROCEDURE
Intervention: Long Arm Splint
Study: NCT01861964

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Maltodextrin)
Description: Maltodextrin 505mg/capsule 8 capsules/day (4 with breakfast and 4 with dinner meal)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xylooligosarcharide 1.4g
Description: 8 capsules (512 mg/capsule) 4 with breakfast and 4 with dinner meal

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xylooligosarcharide 2.8g
Description: 8 capsules (520 mg/capsule) to be taken in the morning and in the evening
Study: NCT00980057

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive CRT (aCRT)
Description: Adaptive CRT (aCRT) is an algorithm, which provides ambulatory adjustment of pacing configuration (LV-only or BiV) and AV and VV delays based on periodic automatic evaluation of electrical conduction to optimize cardiac function

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Echo
Description: Standard BiV pacing with settings optimized using a standardized echocardiographic protocol
Study: NCT00003594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study: NCT02075710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High sugar/meal feed
Description: Weight-maintaining diet relatively high in sugar fed as two large meals daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High sugar/meal feed
Description: Weight-maintaining diet relatively high in sugar fed as two large meals daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High sugar/nibble
Description: Weight-maintaining diet relatively high in sugar fed as 8 meals daily
Study: NCT04307576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin+Standard Maintenance Therapy
Description: Addition of IV Inotuzumab ozogamicin before Maintenance Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: p.o. Imatinib
Study: NCT02075710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High sugar/nibble
Description: Weight-maintaining diet relatively high in sugar fed as 8 meals daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat/meal feed
Description: Weight-maintaining diet relatively high in fat fed as two large meals daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat/nibble
Description: Weight-maintaining diet relatively high in fat fed as 8 small meals daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat/nibble
Description: Weight-maintaining diet relatively high in fat fed as 8 small meals daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High sugar/ 3 meals a day
Description: Weight-maintaining diet relatively high in sugar fed as 3 meals daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High sugar/ 3 meals a day
Description: Weight-maintaining diet relatively high in sugar fed as 3 meals daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat/ 3 meals a day
Description: Weight-maintaining diet relatively high in fat fed as 3 meals daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat/ 3 meals a day
Description: Weight-maintaining diet relatively high in fat fed as 3 meals daily
Study: NCT00506662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Treat-to-target, s.c. (under the skin) injection, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin NPH
Description: Treat-to-target, s.c. (under the skin) injection, once daily
Study: NCT01308554

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: sterile normal saline
Description: Bilateral TAP block using 20 ml of normal sterile saline per block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine
Description: Study group will receive a bilateral TAP block using 20 ml of 0,25% Marcain on each side.
Study: NCT01925677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: da Vinci® Single-Site™
Description: Planned single-incision laparoscopic nephrectomy performed with the assistance of the Da Vinci Robotic Surgical System.
Study: NCT02161731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Oral administration
Study: NCT01408485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapy™ Cool Flex™ Irrigated Ablation System
Description: The investigational components of the Therapy™ Cool Flex™ Irrigated Ablation System consist of:~* Therapy™ Cool Flex™ 4mm Irrigated Ablation Catheter~* IBI 1500T9 V1.43 RF Generator